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Tuberculosis (TB) remains a major cause of illness and death worldwide, making a new TB vaccine an urgent
public health priority. Purified protein derivative (PPD)-negative adults (n  50) were equally randomized to
receive 3 doses at 1-month intervals (at 0, 1, and 2 months) of one of the following vaccines: Mtb72F/AS02A (10
or 40 g antigen), Mtb72F/saline (10 or 40 g antigen), or AS02A. Mtb72F/AS02A recipients received an
additional dose 1 year after the first dose to evaluate if the elicited immune response could be boosted.
Mtb72F/AS02A vaccines were locally reactogenic but clinically well tolerated, with transient adverse events
(usually lasting between 1 and 4 days) that resolved without sequelae being observed. No vaccine-related
serious adverse events were reported. Vaccination with Mtb72F/AS02A induced a strong Mtb72F-specific
humoral response and a robust Mtb72F-specific CD4 T-cell response, both of which persisted at 9 months after
primary immunization and for 1 year after the booster immunization. There was no significant difference between
the magnitude of the CD4 T-cell response induced by the 10-g and 40-g Mtb72F/AS02A vaccines. The Mtb72F-
specific CD4 T cells predominantly expressed CD40L; CD40L and interleukin-2 (IL-2); CD40L and tumor
necrosis factor alpha (TNF-); CD40L, IL-2, and TNF-; and CD40L, IL-2, TNF-, and gamma interferon (IFN-).
Serum IFN-, but not TNF-, was detected 1 day after doses 2 and 3 for the Mtb72F/AS02A vaccine but did not
persist. Vaccine-induced CD8 T-cell responses were not detected, and no immune responses were elicited with
AS02A alone. In conclusion, Mtb72F/AS02A is clinically well tolerated and is highly immunogenic in TB-naïve
adults. The 10- and 40-g Mtb72F/AS02A vaccines show comparable safety and immunogenicity profiles.
Tuberculosis (TB) is a major cause of illness and death
worldwide, causing approximately 1.7 million deaths a year
(43). Despite global efforts to control or eradicate the disease,
the WHO estimates that in 2008 an estimated 8.9 million to 9.9
million people became infected with Mycobacterium tuberculo-
sis. The situation is compounded by the emergence of multi-
drug-resistant TB. Since one-third of the world’s population is
estimated to be latently infected with M. tuberculosis and at
possible risk of disease, TB prevention remains one of today’s
greatest public health challenges. An efficacious vaccination
strategy is an essential tool to control TB.
M. bovis bacillus Calmette-Gue´rin (BCG), consisting of at-
tenuated strains of M. bovis, is the only TB vaccine currently
available. It effectively prevents meningeal and miliary TB in
young children (8) but appears to be ineffective in preventing
adult-onset TB (protection rates, 0 to 80%) (10) and pulmo-
nary TB in children.
GlaxoSmithKline (GSK) Biologicals’ candidate TB vac-
cine antigen, Mtb72F, is composed of a fusion protein de-
rived from two highly immunogenic M. tuberculosis antigens:
Mtb39A (Rv0125 encoding PepA) and Mtb32A (Rv1196 en-
coding PPE18) (34, 35). Mtb72F, formulated with GSK Bio-
logicals’ proprietary AS02A adjuvant system, was shown to be
well tolerated in animal models and protected against M. tu-
berculosis challenge in nonhuman primates, where Mtb72F/
AS02A was shown to be capable of inducing long-term protec-
tion against tuberculosis, as determined by protection against
severe disease and death and by other clinical and histopatholog-
ical parameters (6, 30, 34, 39). A first-time-in-human study eval-
uated Mtb72F/AS02A (10 g) in purified protein derivative
(PPD)-negative TB-naïve, healthy adults in the United States
given according to a 0-, 1-, and 2-month schedule and was found
to be clinically well tolerated and highly immunogenic (42).
This study assessed whether a larger amount of the Mtb72F/
AS02A vaccine antigen (40 g) could improve the elicited
immune response compared with the response elicited by the
previously tested 10-g antigen dose (42). In addition, a fourth
vaccine dose was given to the vaccine recipients to evaluate
whether the immune response could be boosted approximately
1 year after the primary vaccination course.
MATERIALS AND METHODS
Study design and ethics. This phase I open, randomized, controlled trial
(NCT00291889) was conducted between July 2004 and May 2006 at the Center
for Vaccinology, Ghent University Hospital, Ghent, Belgium. The protocol was
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approved by the Ethics Committee of the Ghent University Hospital and was
undertaken in accordance with the Declaration of Helsinki and good clinical
practices. Written informed consent was obtained from all participants before
they entered the study.
The participants were equally randomized to one of five treatment groups,
according to allocation using a central randomization system on the Internet.
The groups were Mtb72F/AS02A (10 or 40 g antigen, investigational vaccines),
Mtb72F/saline (10 or 40 g antigen, active comparators), and AS02A alone
(control). All groups received a primary vaccination course at 0, 1, and 2 months.
Participants receiving Mtb72F/AS02A were given a booster dose 9 months after
completion of the primary vaccination course, approximately 1 year after dose 1,
and were followed for one additional year.
Study population. Healthy adults aged 18 to 45 years were enrolled if they
were seronegative for human immunodeficiency virus (HIV) and hepatitis C
virus (HCV) antibodies and for hepatitis B surface antigen (HBsAg). Partici-
pants were excluded if they had a positive PPD skin test, an abnormal chest X
ray, a history of BCG vaccination, documented exposure to M. tuberculosis, or
potential contact with TB patients. Female participants who were pregnant or
who were planning to become pregnant or to discontinue contraceptive precau-
tions were also excluded.
Study vaccines. Mtb72F was manufactured at Corixa Corporation (now GSK
Biologicals). Physiological saline and AS02A were manufactured at GSK Bio-
logicals, Rixensart, Belgium. AS02A is a proprietary oil-in-water emulsion with
two immunostimulants, monophosphoryl lipid A (MPL) and Quillaja saponaria
fraction 21 (QS21) (14). The vaccines were reconstituted by adding saline or
AS02A to the Mtb72F lyophilized pellet. After gentle shaking of the mixture, a
0.5-ml dose was administered by intramuscular injection into the deltoid muscle
of the nondominant arm. Each 0.5-ml dose of Mtb72F/AS02A and AS02A con-
tained approximately 50 g MPL and 50 g QS21.
Safety and reactogenicity evaluation. Solicited local and general adverse
events (AEs) were recorded on diary cards during a 7-day (including the day of
vaccination) follow-up period after each vaccination and were checked by a study
physician at scheduled visits. Local AEs recorded were injection-site pain, swell-
ing, and redness, as measured by the longest surface diameter. Solicited general
AEs were fatigue, fever (axillary temperature  37.5°C), gastrointestinal symp-
toms (nausea, diarrhea, vomiting, abdominal pain), and headache. Unsolicited
AEs were recorded over a 30-day follow-up period after each vaccination, and
serious AEs (SAEs) were collected throughout the study.
The intensities of the AEs were scored, and grade 3 AEs were defined as AEs
preventing normal daily activity, a temperature of 39.5°C, and swelling or
redness of 50 mm. All local AEs were considered to be related to vaccination.
The relationship of all other AEs to vaccination was determined by the investi-
gator on the basis of best clinical judgment.
Blood hematology and biochemistry parameters (complete blood count, renal
and liver function tests) were measured before and 1 week and 1 month after
each vaccine dose, 6 months after dose 3, and 1 year after the booster.
Immunogenicity evaluation. The cell-mediated immune (CMI) response was
assessed at specific time points by measuring (i) cytokines in serum by enzyme-
linked immunosorbent assay (ELISA) and (ii) immune markers on isolated
peripheral blood mononuclear cells (PBMCs) by an intracellular cytokine stain-
ing (ICS) assay. Anti-Mtb72F antibody concentrations were measured using
ELISA at specific time points.
Intracellular cytokine staining. Mtb72F-specific CD4 and CD8 T cells were
detected using ICS and flow cytometry, based on a previously described method
(24, 25, 42). Briefly, whole-blood samples were collected and PBMCs were
isolated by standard Ficoll-Isopaque density gradient centrifugation and cryo-
preserved in liquid nitrogen. After they were thawed, PBMCs were stimulated in
vitro using individual Mtb32A and Mtb39A 15-mer peptide pools (1.25 g/ml) of
each peptide, covering the entire sequence of the Mtb72F antigen, in the pres-
ence of anti-CD28 and anti-CD49d antibodies (BD Biosciences, Belgium). After
2 h of incubation at 37°C, brefeldin A (BD Biosciences) was added, followed by
an overnight incubation. Cells were stained using peridinin chlorophyll protein
(PerCP)-conjugated anti-CD4 and allophycocyanin (APC) H7-conjugated anti-
CD8 antibodies (BD Biosciences) and were fixed with a Cytofix/Cytoperm buffer
kit (Pharmingen). The fixed cells were permeabilized and stained with the fol-
lowing fluorochrome-conjugated monoclonal antibodies from Pharmingen:
APC-conjugated anti-interleukin-2 (anti-IL-2), fluorescein isothiocyanate
(FITC)-conjugated anti-gamma interferon (anti-IFN-), phycoerythrin (PE)
Cy7-conjugated anti-tumor necrosis factor alpha (anti-TNF-), and PE-conju-
gated anti-CD154 (CD40L). The cells were then washed, resuspended in fetal
calf serum-containing phosphate-buffered saline, and analyzed on a BD LSR II
flow cytometer. The data were analyzed using Diva software (BD Biosciences).
Specific time points were then selected for further analyses of the data with
FlowJo software (Tree Star Inc.).
The in vitro CD4/CD8 T-cell responses to the Mtb72F antigen were plotted
as the sum of the background-subtracted individual Mtb32A and Mtb39A-spe-
cific T-cell responses. The correlation between the in vitro T-cell responses to a
pool of peptides covering the entire Mtb72F antigen and the sum of the indi-
vidual responses to Mtb32A and Mtb39A has been validated in-house (R2 
0.9907).
Cytokines in serum. Commercial ELISA kits were used to measure the levels
of serum IFN- (assay cutoff, 1.0 pg/ml; Becton Dickinson) and TNF- (assay
cutoff, 0.12 pg/ml; R&D Systems Europe Ltd).
Anti-Mtb72F antibody response. The Mtb72F-specific humoral response was
determined by evaluating Mtb72F-specific IgG levels using a previously de-
scribed ELISA (42) with a cutoff 1.0 ELISA units (EU)/ml. Anti-Mtb72F sero-
positivity is described as an antibody concentration of 1 EU/ml. Anti-Mtb72F
antibody concentrations were represented using the geometric mean concentra-
tion (GMC) with 95% confidence intervals (CIs).
Intradermal PPD skin test. At 1 to 3 weeks before the first vaccination and 1
month after completion of the primary vaccination course (day 86), an intrad-
ermal PPD skin test (2 tuberculin units/0.1 ml; tuberculin PPD RT 23 SSI;
Statens Serum Institute) was performed on the dominant arm to assess the effect
of vaccination on PPD status. One dose of the test (0.1 ml) contained 0.04 g
tuberculin PPD. The criterion for negative skin reactivity was 0 mm induration 48
to 72 h after PPD skin test administration.
Statistical methods. All participants who received at least one vaccine dose
were included in the demographic, reactogenicity, and safety analyses. The oc-
currences of solicited and unsolicited AEs are presented as point estimates with
95% CIs.
Immunogenicity analysis was performed on the according-to-protocol (ATP)
data set, which included data for all participants who did not meet any elimina-
tion criteria during the study and for whom immunogenicity data were available.
Significant differences in the magnitude of Mtb72F-specific CD4 T cells
expressing at least 2 immune markers were calculated using the Wilcoxon rank-
sum test.
RESULTS
Study population. Figure 1 presents the participant flow. All
participants were included in the safety analysis. Nineteen sub-
jects returned for the booster dose. Two individuals in the
Mtb72F/AS02A (40-g) group were eliminated from the ATP
analysis for immunogenicity: one withdrew from vaccination
after dose 2 and the other was eliminated for noncompliance
with the blood sampling schedule after dose 3. One participant
from the 10-g Mtb72F/saline group was not included in the
ATP analysis for immunogenicity because he moved away from
the study area after dose 2. The demographics were compara-
ble between all groups. The mean age was 28.7 years (standard
deviation  5.9 years), and all participants were white (Cau-
casian). The overall female-to-male ratio was 1.08 (26 fe-
males/24 males).
Safety and reactogenicity. The Mtb72F/AS02A vaccine for-
mulations were considered to be clinically well tolerated. Most
AEs reported were transient and resolved within 1 to 4 days,
grade 3 AEs resolved or decreased in intensity within 48 h
postvaccination, and the incidence of AEs did not increase
with subsequent immunizations. All AEs resolved without se-
quelae, and in addition, no SAEs were judged by the investi-
gator to be related to vaccination.
Injection-site pain was the most frequently reported AE in
all groups (Table 1) after primary vaccination, with the inci-
dence being comparable between the Mtb72F/AS02A and
AS02A groups (89.7 to 100%, with overlapping CIs). There was
a tendency for a lower frequency of reporting of local AEs in
the Mtb72F/saline groups. The most frequently reported local
grade 3 AE was injection-site swelling, reported only in the
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Mtb72F/AS02A groups (26.7% and 10.3% for the 10-g and
40-g groups, respectively) and the AS02A alone group
(46.7%). There was a trend toward a lower frequency of re-
porting of local grade 3 AEs with the Mtb72F/AS02A (40-g)
vaccine than with the Mtb72F/AS02A (10-g) vaccine and
AS02A. No grade 3 local AEs were reported in the Mtb72F/
saline groups. All solicited local AEs resolved within 5 days of
vaccination.
The most commonly reported solicited general AEs after
primary vaccination were fatigue and headache. The incidence
of fatigue was similar in the Mtb72F/AS02A groups (50.0 to
51.7%) and lower in the control/comparator groups (38%).
The incidence of headache was comparable in all groups and
ranged from 20.7 to 36.7%. Solicited general grade 3 AEs were
infrequent; no cases of grade 3 fever were reported.
The most frequently reported causally related unsolicited
AEs after primary vaccination with Mtb72F/AS02A or AS02A
were transient mild to moderate influenza-like illness (10.0 to
23.3%) and injection-site warmth (23.3 to 30.0%). Causally
related unsolicited AEs were not frequently reported in the
Mtb72F/saline groups (10.3%).
Following booster vaccination with the Mtb72F/AS02A vac-
cines, comparable frequencies of unsolicited AEs were ob-
served, with transient mild to moderate influenza-like illness
(15.0 to 20.0%) and injection-site warmth (26.0 to 30.0%)
being the most frequently reported AEs. No increase in the
overall frequency of AEs was observed, and the frequencies
were comparable in both Mtb72F/AS02A vaccine groups.
No clinically relevant changes in the biochemistry or hema-
tology parameters were noted throughout the study (results
not shown).
Two SAEs were reported during the study period. One in-
dividual in the Mtb72F/AS02A (40 g) group reported appen-
dicitis, and one in the Mtb72F/AS02A (10 g) group suffered a
broken ankle. Both SAEs were judged to be not related to
vaccination by the investigator.
Immunogenicity. (i) CD4 and CD8 T-cell responses by
ICS and flow cytometry. In order to evaluate the magnitude of
the cell-mediated immune response elicited by the Mtb72F/
AS02A vaccines, PBMCs were restimulated in vitro and ana-
lyzed by ICS and flow cytometry. A high frequency of Mtb72F-
specific CD4 T cells expressing two or more immune markers
among the markers CD40L, IL-2, TNF-, and IFN- was mea-
sured after 2 and 3 immunizations for 10 g Mtb72F/AS02A
(median frequencies, 0.19% and 0.23%, respectively) and 40
g Mtb72F/AS02A (median frequencies, 0.28% and 0.15%,
respectively) (Fig. 2). These responses were significantly higher
than those for their respective saline comparators (Wilcoxon
rank-sum test, P 0.05 at 1 month after doses 2 and 3 for both
the 40-g and 10-g vaccines).
The magnitude of the CD4 T-cell response at 1 month
after dose 2 (day 56) was not significantly different from the
response at 1 month after dose 3 (day 86) for either the 10- or
40-g Mtb72F/AS02A vaccines (Wilcoxon rank-sum test, P 
0.93 and P  0.13, respectively).
Boosting by a fourth vaccine dose did not increase the mag-
nitude of the CD4 T-cell response (at 1 month postbooster,
day 338) in either of the Mtb72F/AS02A vaccine groups be-
FIG. 1. Participant flow. M:F, ratio of males to females; NA, not applicable. *, two subjects from the Mtb72F (40 g)/AS02A group were
eliminated from the ATP immunogenicity analysis: one subject withdrew from vaccination at dose 3, and the other subject was out of interval for
blood samples; **, one subject from the Mtb72F (40 g)/saline group was not included in the ATP immunogenicity analysis because he moved
away from the study area after dose 2.
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yond that observed after the second and third immunizations.
However, these cellular responses persisted at 1 year post-
booster (day 644).
The magnitude of the CD4 T-cell responses induced by the
10-g and 40-g Mtb72F/AS02A vaccines were not signifi-
cantly different from each other at 1 month after dose 2 (day
56; Wilcoxon rank-sum test, P  0.47), 1 month after dose 3
(day 86; Wilcoxon rank-sum test, P  0.74), 9 months after
dose 3 (day 308; Wilcoxon rank-sum test, P 0.64), and 1 year
postbooster (day 644; Wilcoxon rank-sum test, P  0.36).
No Mtb72F-specific CD4 T-cell response was observed in
the AS02A group.
No vaccine-induced Mtb72F-specific CD8 T cells were de-
tected (data not shown).
Functional characterization of the Mtb72F-specific CD4 T
cells showed that both Mtb72F/AS02A vaccines induced poly-
functional CD4 T cells after vaccination, which persisted
(Fig. 3A and B). The predominant phenotypes of the vaccine-
induced Mtb72F-specific CD4 T cells were CD40L IL-2,
CD40L TNF-, polyfunctional CD40L IL-2 TNF-,
and to a lesser extent, polyfunctional CD40L IL-2 IFN-
TNF-. Low frequencies of monofunctional CD4 T cells
expressing IL-2, TNF-, or IFN- were also induced. High
frequencies of antigen-specific CD4 T cells expressing only
the activation marker CD40L were elicited by Mtb72F/AS02A.
(ii) Serum IFN- and TNF- responses by ELISA induced
by Mtb72F/AS02A vaccines. To evaluate whether the Mtb72F/
AS02A vaccine upregulated the expression of Th1 cytokines in
the blood, IFN- and TNF- levels were evaluated shortly
after vaccine administration. No vaccine-induced serum IFN-
was detected after dose 1 in the majority of the individuals
(Fig. 4). IFN- was detected in the serum at 1 day after doses
2 and 3 (days 29 and 57, respectively) but had decreased to
baseline levels at 6 days after doses 2 and 3 (days 34 and 62,
respectively). At 1 day postbooster (day 309), median serum
levels of IFN- were comparable to those detected at 1 day
after dose 3 (day 57) in the Mtb72F/AS02A groups. Only base-
line responses were observed in the Mtb72F/saline and AS02A
groups (data not shown). To investigate whether these cyto-
kines were induced early after vaccination, blood samples from
additional postbooster time points were evaluated. However,
no IFN- was detected at 2, 4, and 6 h postbooster. No TNF-
was detected in any of the groups at any time points tested
(data not shown).
(iii) Mtb72F-specific antibody responses. Two weeks after
the second vaccine dose (day 42), all participants who had
received Mtb72F/AS02A were seropositive for anti-Mtb72F
IgG antibodies (Fig. 5). During the primary vaccination course,
peak levels of anti-Mtb72F antibodies were measured at 2
weeks after dose 3 (day 70). There was a trend toward in-
TABLE 1. Incidence of solicited adverse events reported during the 7-day follow-up period after all vaccinations
of the primary vaccination phase
AE
% AEs reported (95% CI) for each vaccine group
Mtb72F (10 g)/
AS02A (na  30)
Mtb72F (40 g)/
AS02A (n  29)
Mtb72F (10 g)/
saline (n  29)
Mtb72F (40 g)/
saline (n  30) AS02A (n  30)
Local AEs
Pain
All 90.0 (73.5–97.9) 89.7 (72.6–97.8) 17.2 (5.8–35.8) 30.0 (14.7–49.4) 100.0 (88.4–100.0)
Grade 3 10.0 (2.1–26.5) 3.4 (0.1–17.8) 0.0 (0.0–11.9) 0.0 (0.0–11.6) 20.0 (7.7–38.6)
Redness
All 36.7 (19.9–56.1) 6.9 (0.8–22.8) 0.0 (0.1–17.2) 3.3 (0.0–11.9) 23.3 (9.9–42.3)
Grade 3 16.7 (5.6–34.7) 0.0 (0.0–11.9) 0.0 (0.0–11.9) 0.0 (0.0–11.6) 16.7 (5.6–34.7)
Swelling
All 53.3 (34.3–71.7) 31.0 (15.3–50.8) 3.4 (0.8–22.1) 6.7 (0.1–17.8) 60.0 (40.6–77.3)
Grade 3 26.7 (12.3–45.9) 10.3 (2.2–27.4) 0.0 (0.0–11.9) 0.0 (0.0–11.6) 46.7 (28.3–65.7)
General AEs
Fatigue
All 50.0 (31.3–68.7) 51.7 (32.5–70.6) 37.9 (20.7–57.7) 26.7 (12.3–45.9) 20.0 (7.7–38.6)
Grade 3 10.0 (2.1–26.5) 6.9 (0.8–22.8) 0.0 (0.0–11.9) 0.0 (0.0–11.6) 0.0 (0.0–11.6)
Feverb
All 13.3 (3.8–30.7) 10.3 (2.2–27.4) 3.4 (0.1–17.8) 0.0 (0.0–11.6) 3.3 (0.1–17.2)
Grade 3 0.0 (0.0–11.6) 0.0 (0.0–11.9) 0.0 (0.0–11.9) 0.0 (0.0–11.6) 0.0 (0.0–11.6)
Gastrointestinalc
All 16.7 (5.6–34.7) 17.2 (5.8–35.8) 20.7 (8.0–39.7) 16.7 (5.6–34.7) 20.0 (7.7–38.6)
Grade 3 0.0 (0.0–11.6) 6.9 (0.8–22.8) 3.4 (0.1–17.8) 0.0 (0.0–11.6) 3.3 (0.1–17.2)
Headache
All 33.3 (17.3–52.8) 34.5 (17.9–54.3) 20.7 (8.0–39.7) 26.7 (12.3–45.9) 36.7 (19.9–56.1)
Grade 3 0.0 (0.0–11.6) 0.0 (0.0–11.9) 0.0 (0.0–11.9) 3.3 (0.1–17.2) 0.0 (0.0–11.6)
a n, total number of doses administered.
b Fever was defined as an axillary temperature of 37.5°C (99.5°F).
c Gastrointestinal AEs were nausea, vomiting, diarrhea, and/or abdominal pain.
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creased humoral responses with 40 g Mtb72F/AS02A com-
pared to those with 10 g Mtb72F/AS02A. All but one vaccinee
in the Mtb72F/saline groups became seropositive at 2 weeks
after dose 3 (day 70), but the GMCs were significantly lower
with no overlapping CIs compared with the values for the
Mtb72F/AS02A groups (13.1 and 31.3 EU/ml for the 10- and
40-g Mtb72F/saline groups, respectively).
Antibody responses after primary vaccination with Mtb72F/
AS02A persisted over 9 months. A fourth administration of the
Mtb72F/AS02A vaccines boosted the antibody response, and 1
month later (day 338), they were approximately twice those
observed after dose 3 (753.7 and 354.9 EU/ml after doses 4 and
3, respectively, for the 10-g antigen dose and 938.3 and 581.4
EU/ml after doses 4 and 3, respectively, for the 40-g antigen
dose). All subjects receiving Mtb72F/AS02A remained sero-
positive at 1 year after the booster dose. No anti-Mtb72F IgG
response was observed in the AS02A group.
(iv) PPD skin test reactivity. To assess whether vaccination
with Mtb72F/AS02A had an effect on PPD status, participants
were evaluated 1 month after the primary vaccination course
(i.e., day 86 after the first vaccine dose) by intradermal PPD
skin test. None of the participants converted from PPD-nega-
tive to PPD-positive status during the study.
DISCUSSION
The safety, reactogenicity, and immunogenicity of Mtb72F/
AS02A have recently been evaluated in PPD-negative U.S.
adults (42). This randomized, controlled study allowed a better
evaluation of safety and was also designed to provide a justi-
fication for use of the adjuvant. Therefore, the reactogenicity
and immunogenicity induced by the adjuvanted vaccine (Mtb72F/
AS02A) were compared to those of the antigen in saline
(Mtb72F/Saline) and the adjuvant alone (AS02A). A head-to-
head comparison was also needed to examine whether a higher
concentration of antigen (40 g) was well tolerated and was
able to elicit better immune responses compared to those elic-
ited with the 10-g concentration used previously. Here we
also assessed if a fourth vaccine administration could boost the
persistent immune responses. Finally, the quality of the T-cell
response was extensively analyzed in order to achieve a full
characterization of the vaccine-elicited mono- and polyfunc-
tional T-cell phenotypes. This study demonstrates that up to
four immunizations with the Mtb72F/AS02A vaccine (10 and
40 g) are clinically well tolerated in PPD-negative healthy
adults. No vaccine-related SAEs were reported. The local re-
actogenicity profile of Mtb72F/AS02A was comparable to that
FIG. 2. Frequency of Mtb72F-specific CD4 T cells expressing at least two immune markers among IFN-, IL-2, TNF-, and CD40L. PBMCs
from blood samples from all study groups were obtained at prevaccination (day 0), 2 weeks after dose 2 (day 42), 1 month after dose 2 (day 56),
2 weeks after dose 3 (day 70), 1 month after dose 3 (day 86), and 6 months after dose 3 (day 224). The Mtb72F/AS02A-vaccinated groups were
followed up prebooster (day 308), 1 month postbooster (day 338), and 1 year postbooster (day 644). PBMCs were evaluated by ICS and flow
cytometry after short-term in vitro stimulation with overlapping 15-mer peptide pools spanning the Mtb32A and Mtb39A proteins. Data are
represented in box-and-whiskers plots as the number of Mtb72F-specific CD4 T cells expressing at least two immune markers per 106 CD4 T
cells. Arrows indicate the time of vaccination.
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seen with AS02A alone. Fewer AEs were observed in the
Mtb72F/saline groups, suggesting that AS02A rather than the
Mtb72F antigen contributes to the observed injection-site re-
actions. The solicited general AEs fatigue and fever were re-
ported more frequently in the Mtb72F/AS02A groups than in
the Mtb72F/saline or AS02A groups, suggesting that this may
be the expected consequence of the vigorous antigen-specific
immune response observed after Mtb72F/AS02A administra-
tion. All AEs reported were transient, and most resolved
within 1 to 4 days. The pattern of AEs observed has previously
been reported with other vaccines containing AS02A (14, 16,
37, 40–42). No clinically significant changes in laboratory test
(biochemistry and hematology) values related to vaccination
were observed. In a study described in a previous publication
(42), eosinophilia and decreased hemoglobin levels were fre-
quently reported when the vaccine was given to healthy PPD-
FIG. 3. Polyfunctional profiles of Mtb72F-specific CD4 T cells expressing any combination of immune markers among IFN-, IL-2, TNF-,
and CD40L. PBMCs from subjects vaccinated with 10 g Mtb72F/AS02A (A) and 40 g Mtb72F/AS02A (B) were obtained at prevaccination (day
0), 2 weeks after dose 2 (day 42), 2 weeks after dose 3 (day 70), prebooster (day 308), 1 month postbooster (day 338), and 1 year postbooster (day
644). PBMCs were evaluated using ICS and flow cytometry after short-term in vitro stimulation with 15-mer peptide pools spanning the Mtb32A
and Mtb39A antigens. Data are represented in box-and-whiskers plots as the number of Mtb72F-specific CD4 T cells expressing single markers
and any combination of IFN-, IL-2, TNF-, and/or CD40L per 106 CD4 T cells.
1768 LEROUX-ROELS ET AL. CLIN. VACCINE IMMUNOL.
negative adults, although these were reported to be mainly
mild and not clinically significant. In this study, which was
controlled, in contrast to the previous study, which had no
comparators, there were infrequent and comparable reports of
mild eosinophilia and a decrease in hemoglobin levels in all
vaccine and control groups (maximum of 1 to 3 individuals per
group). Most of these mild fluctuations occurred either at
prevaccination or screening, and no vaccination-related pat-
tern emerged. These reports were also not considered to be
clinically significant, in line with what was previously reported.
It is interesting to note that there appeared to be a trend
toward a lower frequency of reporting of AEs in the 40-g
Mtb72F/AS02A group than in the 10-g Mtb72F/AS02A and
AS02A groups. However, given the small sample size and
overlapping CIs, this observation appears not to be clinically
significant. The Mtb72F/AS02A vaccines induced a strong
Mtb72F-specific CD4 T-cell response compared to that in-
duced by Mtb72F/saline, showing that the AS02A adjuvant
system enhanced the immunogenicity of the Mtb72F antigen.
No Mtb72F-specific immune responses were observed in the
group receiving AS02A alone.
A robust CD4 T-cell response was induced after two doses
of Mtb72F/AS02A, with no increase in the magnitude of the
response occurring after a third and a fourth vaccine dose.
The Mtb72F-specific CD4 T-cell response was persistent in
the Mtb72F/AS02A vaccine groups at 9 months after the pri-
mary vaccination course. A booster dose increased Mtb72F-
specific CD4 T-cell responses to magnitudes comparable to
those observed after primary vaccination and persisted at 1
year postbooster, suggesting that memory CD4 T cells may
have been induced. There was no significant difference be-
tween the magnitude of the CD4 T-cell response induced by
the 10-g and 40-g Mtb72F/AS02A vaccines. The magnitude
of the response after 1 month after dose 3 was comparable to
that seen previously with the 10-g Mtb72F/AS02A vaccine
when it was tested in PPD-negative U.S. adults (10). Func-
tional characterization showed that Mtb72F-specific polyfunc-
tional CD4 T cells were induced by both Mtb72F/AS02A
vaccines and persisted 1 year after boosting. The predomi-
nant CD4 T-cell phenotypes were CD40L, CD40L IL-
2, CD40L TNF-, and CD40L IL-2 TNF-.
Mtb72F/AS02A also induced Mtb72F-specific CD40L
 IL-2
TNF- IFN- CD4 T cells, albeit at a lower frequency.
Remarkably, a higher frequency of single positive CD40L
CD4 T cells was also observed, indicating that a distinct
population of antigen-specific activated CD4 T cells was elic-
ited by the Mtb72F/AS02A vaccine. This is the first study which
demonstrates the polyfunctionality of vaccine-induced CD4 T
cells in PPD-negative subjects. Other studies of TB vaccine
FIG. 4. Serum IFN- levels after Mtb72F/AS02A vaccine adminis-
tration. Serum from subjects vaccinated with 10 g Mtb72F/AS02A
and 40 g Mtb72F/AS02A were obtained on the day of vaccination
(days 0, 28, 56, and 308), 1 day later (days 1, 29, 57, and 309), and 6
days later (days 6, 34, and 62) and were evaluated using ELISA to
measure serum levels of IFN-. Data are represented in box-and-
whiskers plots with a line at the median response and lower and higher
quartiles. Whiskers indicate minimum and maximum responses.
FIG. 5. Anti-Mtb72F IgG antibody responses. Serum samples from
all groups were obtained prevaccination (day 0), 2 weeks after dose 2
(day 42), 1 month after dose 2 (day 56), 2 weeks after dose 3 (day 70),
1 month after dose 3 (day 86), and 6 months after dose 3 (day 224).
The Mtb72F/AS02A-vaccinated groups were followed up prebooster
(day 308), 1 month postbooster (day 338), and 1 year postbooster (day
644) and were evaluated by ELISA. The Mtb72F-specific IgG antibody
responses are represented using geometric mean concentrations with
95% CIs. Arrows indicate the time of vaccination.
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candidates have demonstrated polyfunctional CD4 T-cell re-
sponses in PPD-positive adults (2, 5, 18, 31). Earlier work
showed that the MVA85a TB vaccine candidate was immuno-
genic in PPD-negative British adults and that the magnitude of
the IFN- enzyme-linked immunospot assay response was pos-
itively influenced by BCG priming (26).
Our results are promising, since studies in mouse models
showed that induction of polyfunctional T cells correlated with
protection against tuberculosis (1, 19) and that assessment in
humans of T-cell polyfunctionality might allow more accurate
identification of a protective T-cell population (9). Moreover,
it is generally accepted that the induction of cellular Th1 im-
mune responses is associated with protection against TB (36).
CD4 T cells are believed to contribute to protection against
M. tuberculosis by the production of Th1 cytokines. Among
these cytokines, IFN- (3, 4, 22, 36) and TNF- (11, 28) seem
to be the central effector molecules, leading to autophagy,
mycobacterial killing, and macrophage death (12, 17, 21, 29,
33). IL-2 is a potent inducer of T-cell proliferation and differ-
entiation and is key to the optimal survival and function of
memory cells (20). CD40 ligand has been identified as a
marker for activated antigen-specific T cells; it is a costimula-
tory ligand needed to provide T-cell help (7, 13, 38). A role for
CD8 T cells in the protection against TB has been demon-
strated (15, 23, 27, 32). Similar to results from an earlier study
with Mtb72F/AS02A (42) and studies with the MVA85a TB
vaccine candidate (5, 18, 31), no vaccine-induced antigen-spe-
cific CD8 T cells could be detected by ICS using a short-term
in vitro restimulation.
We demonstrated that vaccination with Mtb72F/AS02A in-
duced IFN- secretion in the serum at 1 day after vaccination.
No TNF- was detected. The transient presence of IFN- in
the serum was clearly linked to Mtb72F/AS02A vaccination, as
no such response was observed in the other study groups.
Robust and persistent antibody responses were induced by
the Mtb72F/AS02A vaccines, with 100% seropositivity occur-
ring after the second dose. Each vaccine administration in-
creased the humoral immune response during the primary
vaccination course, and the antibody responses induced by the
Mtb72F/AS02A vaccines were significantly higher than those
induced by their Mtb72F/saline counterparts. Anti-Mtb72F ti-
ters tended to be higher in the Mtb72F/AS02A (40-g) group
than in the Mtb72F/AS02A (10-g) group in the primary vac-
cination course. The antibody response could be boosted to the
same level for both Mtb72F/AS02A vaccines by a fourth dose 9
months later. All subjects remained seropositive 1 year post-
booster.
The contribution of humoral responses in protection against
TB is somewhat controversial, but it has been suggested that
antibody-mediated immunity can alter the course of M. tuber-
culosis infection in certain situations (15).
In conclusion, the Mtb72F/AS02A candidate vaccine is clin-
ically well tolerated and highly immunogenic in PPD-negative
adults. A favorable safety profile was observed with 4 injections
of the two Mtb72F/AS02A vaccines (10 g and 40 g) tested in
this study. The vaccine induced a robust Mtb72F-specific hu-
moral and polyfunctional CD4 T-cell response.
The next steps in the clinical development of this vaccine will
be to evaluate Mtb72F/AS02A in adults who are PPD positive,
either from natural exposure to M. tuberculosis or from prior
vaccination with BCG, and to initiate its evaluation in individ-
uals living in regions where TB is endemic.
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